Physician profile
Deborah E Schiff
NPI 1922179779
$3,357.44
in general payments reported to CMS, 2019-2025
7 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $15.85 · 2021: $115 · 2022: $149 · 2023: $1,680 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,517 · Food and Beverage: $254 · Consulting Fee: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,517.14 |
| Food and Beverage | $254.39 |
| Consulting Fee | $111.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $1,680.01 | 2023 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $1,078.69 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $243.59 | 2019-2022 | |
| Incyte Corporation | $220.55 | 2021-2025 | Niktimvo |
| Genetix Biotherapeutics INC | $96.72 | 2025 | Lyfgenia |
| Servier Pharmaceuticals LLC | $37.88 | 2019-2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Schiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.